Female mice of inbred strain CBA do not reject syngeneic male skin grafts even though they mount a T-cell response against the malespecific HY antigen. We show that local immunostimulation performed by injecting cytokines and Toll-like receptor ligands in close vicinity to the graft causes rejection. We feel that this approach should be tested in tumor-bearing human patients in combination with antitumor vaccination. Relief of intratumor immunosuppression may increase considerably the fraction of patients who respond to vaccination directed against tumor antigens recognized by T cells.
Female mice of inbred strain CBA do not reject syngeneic male skin grafts even though they mount a T-cell response against the malespecific HY antigen. We show that local immunostimulation performed by injecting cytokines and Toll-like receptor ligands in close vicinity to the graft causes rejection. We feel that this approach should be tested in tumor-bearing human patients in combination with antitumor vaccination. Relief of intratumor immunosuppression may increase considerably the fraction of patients who respond to vaccination directed against tumor antigens recognized by T cells.
immunology | transplantation T he identification of the antigens recognized on human tumors by autologous T lymphocytes demonstrated that a majority of these antigens are highly tumor-specific (1, 2) . Moreover, many of these antigens were found to be encoded by "cancer-germline" genes such as the MAGE family of genes, which are expressed by a large fraction of tumors of various histological types. This finding opened the possibility of vaccinating large groups of cancer patients with the same antigen to elicit T-cell responses able to destroy the cancer cells without damaging normal cells. Human tumors were also found to bear strictly tumor-specific antigens resulting from point mutations affecting ubiquitously expressed genes. These antigens are rarely shared by different tumors. Finally, melanoma patients also have T cells directed against melanocytic differentiation antigens, contrary to the expectation that natural tolerance ought to prevent such responses (1, 3) .
The initial clinical trials with cancer vaccines were performed on melanoma patients with detectable metastatic disease. Small trials involving vaccination with MAGE antigens confirmed the expectation that complete or partial tumor responses could be obtained in the absence of autoimmunity (4, 5) . However, these clinical responses were observed in only 5-10% of the patients, with no sign of tumor regression observed in the vast majority. Because these first vaccination trials were performed with antigenic peptides in the absence of adjuvant, it was widely expected that the use of more potent vaccines, such as viral recombinant vaccines or peptidepulsed dendritic cells, would produce improved results. However, more than a decade of such vaccination trials has failed to provide significant improvement of clinical efficacy (6) .
The initial view of the process elicited by vaccination in responding patients was that antivaccine cytolytic T lymphocytes (CTL) would migrate in large numbers to tumor sites and directly destroy the tumor cells. We believe that this view is erroneous. First, even in patients who experience a clinical response, there are insufficient numbers of antivaccine T cells. The analysis of T cells present in peripheral blood indicates that most of these patients have at best a barely detectable antivaccine T-cell response (7) . In some clinical responders, we evaluated the number of antivaccine T cells present in tumor deposits, and we concluded that they are present at a ratio of less than one in a million relative to tumor cells. Moreover, much larger numbers of T cells directed against other tumor-specific antigens are already present within the tumor before vaccination, and some of these T-cell populations expand considerably when rejection occurs.
The presence of tumor-infiltrating lymphocytes (TILs) with potential antitumor activity was observed as early as 1988 by Rosenberg and his associates (8) , who cultured single-cell suspensions of metastases in the presence of interleukin-2 (IL-2) and obtained large numbers of lymphocytes that exerted cytolytic activity on fresh tumor cell preparations, albeit under conditions where conclusive specificity controls could not be carried out (8, 9) . The detailed identification of the set of tumor-specific antigens expressed by some tumors enabled us to examine TILs under conditions where the antigenic target and T-cell receptor sequence were identified. This led to the demonstration that before vaccination TILs directed against several of these tumorspecific antigens are indeed present in the tumor. After vaccination, in patients who make clinical responses, many TIL clonotypes analyzed within the tumor were found to be considerably amplified, with frequencies about 1,000-fold higher than that of the antivaccine TILs. Dominant clonotypes that were absent before vaccination, were also observed. Collectively, this diverse set of expanding antitumoral TILs reached a frequency of 1% relative to the tumor cells (10) .
On the basis of these and other findings, it is now clear that most melanoma patients produce a spontaneous T-cell response
Significance
Many cancer patients mount a spontaneous T-lymphocyte response against their tumor. In metastatic progressing patients, this response has evidently been incomplete. Moreover, it has stalled, and an immunosuppressive environment appears to be present within the tumor. This may constitute a major factor preventing success of immunotherapies such as antitumoral vaccination. Similar stalled responses are occasionnally observed in the area of tissue transplantation. In a mouse strain named CBA, this phenomenon is observed when male skin is grafted onto females. We used this system to find combinations of cytokines and Toll receptor ligands that, when applied locally, relieve the immunosuppression and reactivate the response. The combinations reported here may prove generally useful to boost the efficacy of cancer immunotherapy.
against their tumor (7) . In many patients, this attempt at eliminating the tumor evidently fails and a large number of antitumor T cells remain in an inactive state in circulation and within tumor deposits. Inside the tumors, this anergic state appears to be reinforced by an immunosuppressive environment. For the vaccinated patients who show tumor regression, we propose the following sequence of events: a very small number of active antivaccine T cells penetrates the tumor and attacks some tumor cells. As a result, these CTL are restimulated and produce cytokines that focally reverse the local immunosuppression, creating instead an immunostimulatory environment. This reawakens many of the inactive antitumor T cells that are already present in significant numbers in situ. Naive antitumor T cells may also be activated. The mobilization of all these T cells, most of which are directed against tumor antigens other than the vaccine antigen, provides the large numbers of effector cells required to reject the tumor.
Why is it that, following vaccination, tumors regress in some patients whereas no sign of regression is observed in most patients? A first possibility is that this may be due to differences in the quantity or quality of T cells responding to the vaccine. The lack of improvement of clinical outcome following highly immunogenic vaccination suggests that the strength of the response to the vaccine is not the limiting factor. A second possible difference between regressing and nonregressing patients could be the degree of expression of the relevant antigens on the surface of tumor cells. It is well established that tumors can lose the expression of some or all of their HLA molecules (1, 11, 12) . However, we derived melanoma cell lines from a large number of nonresponder patients, and almost all of them proved to be sensitive to antivaccine CTL in vitro. We therefore suspect that loss of antigen expression accounts for only a small fraction of the treatment failures. A third possible explanation for the individual differences in clinical response is that patients vary in the degree of immunosuppression present in their tumor. A highly immunosuppressive tumor environment could render the antivaccine T cells inactive soon after penetrating the tumor, preventing them from initiating the cascade of events that leads to tumor rejection. The responder patients would be those who have a lower degree of immunosuppression in their tumor.
The anergic state of tumor-infiltrating lymphocytes and the immunosuppressive tumor environment are often considered to result from an active immunosuppressive mechanism of tumor cells acquired in the course of the selection for resistance to the immune response. Agents such as indoleamine 2,3-dioxygenase, tryptophan 2,3-dioxygenase, and TGF-β are produced in many tumors and unquestionably contribute to inducing the anergy of infiltrating lymphocytes (13) (14) (15) . However, it is also possible that where the immune system makes a rather weak attempt to eliminate a tissue, as expected in the absence of pathogenassociated molecular patterns binding to Toll-like, Nod, and RIG receptors, after a length of time the immune system enters an inactive state. Examples of such "immune fatigue" are observed in human transplantation: a small number of recipients can be withdrawn from treatment with immunosuppressive agents without deleterious effects in the grafted organ (16, 17) . This process, whereby an incomplete response evolves into an anergic state, could be common to all progressive metastatic tumors, whereas the presence and the nature of immunosuppressive factors secreted by tumor cells are likely to vary from one tumor to another. The common anergic state could involve a degree of immunosuppression within the tumor, resulting in potential paralysis of incoming T lymphocytes.
If the degree of intratumor immunosuppression is the limiting factor for the success of vaccination against tumors, the use of cytokines to alleviate this immunosuppression could improve the outcome. A considerable amount of effort has been devoted to testing systemic cytokine treatment in cancer patients. Impressive results have been obtained in a number of patients treated with IL-2 and IFN-α, but at the dosage required for efficacy significant toxicity has been observed (8, 18) . We feel that, in contrast, local cytokine treatment of metastases should be tested as an adjunct to vaccination. This local treatment could enable the antivaccine T cells to initiate the rejection process. Moreover, the amount of agents used for local treatment would be orders of magnitude below those used for systemic treatments, thereby reducing the occurrence of adverse side effects. We realize that this approach will lead to therapeutic progress only if the immune rejection response of the treated metastasis leads to the production of antitumor T cells of such quantity and quality that they successfully attack untreated metastases disseminated elsewhere in the body.
We present here a set of observations related to local immunostimulation with cytokines and Toll-like receptor (TLR) ligands. We wanted to address first the common component of anergy, referred to above as "immune fatigue." To this end, we carried out preclinical studies using the mouse HY system, which involves T-cell responses to antigens expressed in male and not in female tissues. This model is attractive as it has several features shared with the immune response to human tumors. Whereas inbred mouse strain C57BL/6 (H2 b ) females reject syngeneic male skin grafts, CBA (H2 k ) females do not, even though we have observed that a CTL response directed against HY antigens does occur following grafting. Thus, the process observed in CBA is similar to that observed in progressing human tumors: a failed attempt at rejection followed by the persistence of ineffective memory T cells. Moreover, in contrast with most mouse tumors, skin grafts can be followed and manipulated over a period of several months, a situation similar to that encountered with most human tumors. We report below that some locally administered cytokine combinations are effective in promoting the rejection of these skin grafts.
Results
As shown in Fig. 1 (19, 20) . We observed that female CBA mice produce CTL against male target cells expressing both peptides after grafting with syngeneic male, but not female, skin.
Local Treatment with IL-12 and IFN-α. We tested various immunostimulatory agents to identify combinations that are able to promote graft rejection following local treatment in the absence of notable toxicity.
A number of CBA females grafted with male skin were treated with IL-12 and with IFN-α (Fig. 2) . Small volumes were injected % specific lysis s.c. under the graft. This local treatment was administered for 3 consecutive days every week either until complete graft rejection or until the end of the fifth week. IFN-α at a dosage of 10 5 units had no effect. IL-12 administered alone was effective at 1,000 units. Clear synergy was observed between the two cytokines, resulting in complete rejection of all of the grafts following local treatment with 100 units of IL-12 combined with 10 5 units of IFN-α. No symptoms of toxicity were observed.
Effector to target ratio
The observed rejections do not appear to be due to a nonspecific local toxicity of the cytokines as female skin grafts were not rejected (Fig. S1) . Moreover, they seem to result principally from a local as opposed to a systemic effect of the cytokines, as i.p. injections of the same dose of cytokines were clearly much less effective (Fig. S2A) . Whereas some rejections could be observed after treating the graft for only 1 wk, 5 wk of treatment were necessary to elicit virtually 100% rejection (Fig. S3) . The treatment involving IL-12 and IFN-α was less effective when given 100 d after grafting rather than after 20 d: 60% versus 100% of the mice showed rejection. This may be due to a decrease in the level of immune memory, likely to diminish between 3 and 12 wk after grafting. Alternatively, this effect may be due to a gradual decrease of the local inflammation resulting from the surgical grafting process.
IFN-α was not the only cytokine capable of causing graft rejection in combination with IL-12. IL-1α, IL-2, and IL-18 also showed definite synergies. So did gardiquimod, a ligand of TLR7 (Table S1 ).
Interleukin 2, IFN-α, Granulocyte-Macrophage Colony-Stimulating Factor, and Gardiquimod. Considering the difficulty and delays encountered in performing clinical trials with drugs that have not yet been approved for human use, we resorted to our preclinical model to test a combination of IL-2, IFN-α, and granulocytemacrophage colony-stimulating factor (GM-CSF), which are drugs registered for clinical use. Because repeated local injections of 300 ng of IL-2 mixed with 10 5 units of IFN-α and 300 ng of GM-CSF had little effect, we added to the mixture 20 μg of gardiquimod, as it is similar to the TLR7 ligand imiquimod, which is approved for human use. This resulted in the rejection of the male skin grafts in the absence of notable toxicity (Fig. 3) . The effect was due to a local and not to a systemic action of the agents, as i.p. injection had no effect (Fig. S2B) . Female skin grafts were not rejected. The full effect was maintained when GM-CSF was omitted. The combination of gardiquimod and IL-2 was almost as effective as the complete combination. Increasing the dosage of IL-2 to 3 μg accelerated rejection and caused no obvious
In contrast to the combination of IL-12 and IFN-α, a gardiquimod + IL-2 + IFN-α + GM-CSF treatment initiated 100 d after the grafting of the male skin proved as effective as a treatment initiated at 22 d (Fig. S4) .
With the combination of gardiquimod, IL-2, IFN-α, and GM-CSF, we re-examined the need for repeating local injections for several weeks. As shown in Table 1 , in a group of 30 mice, ongoing rejection was observed in 18 mice after 2 wk. For 9 of those mice, the treatment was halted, and 6 mice proceeded to complete rejection. For the other 9, the treatment was pursued, leading to eight complete rejections. We conclude that, among the mice that show an early onset of rejection, most can complete the rejection process without further local stimulation. The picture was quite different for the 12 mice that displayed a later onset of rejection, i.e., after 3-5 wk: none of those whose treatment was arrested then rejected their grafts completely, whereas most mice with maintained treatment eventually rejected their grafts.
We examined whether other agents could complement the local action of the IL-2 and IFN-α combination. A combination of anti-TGFβ1 and anti-IL-10 showed efficacy. So did a combination of anti-CTLA-4, anti-PDL1, and GM-CSF. However, neither combination was as effective as gardiquimod (Table S2) .
Effect of Various Cytokines on Graft Invasion by T Cells.
To begin evaluating the action of the various immunostimulatory agents that proved capable of promoting graft rejection, we examined their ability to promote the presence of anti-HY CD8 T lymphocytes in the graft. We used CD8 T cells from spleens of T-cell receptor transgenic mice expressing a receptor specific for the K k HY peptide described above. After i.p. adoptive transfer, the number of transgenic T cells present in any given location could be estimated by a quantitative PCR specific for this receptor sequence. No increase in the number of anti-HY transgenic T cells present in the graft was observed following treatment with either IFN-α or GM-CSF. In contrast, gardiquimod, IL-12, and IL-2 produced a very significant increase (Table 2 ). We are unable to evaluate whether this increase is due mainly to increased influx, increased proliferation within the graft, or decreased efflux. The agents that cause a large increase in the number of anti-HY T cells found in the graft also cause a moderate increase of these cells in the blood and in the spleen. This could be due to some systemic action of these agents, or it could be a consequence of T-cell circulation between these compartments and the graft. We verified that the local cytokine treatment does not elicit a nonspecific influx of lymphocytes: no increase in lymphocytes was observed within female grafts.
Local Immunostimulation Combined with Vaccination. We next examined whether the local effect of cytokines could be boosted by vaccinating the mice with male antigen after graft healing. This is a situation similar to that encountered in cancer patients who receive therapeutic antitumor vaccination. For this purpose, we reduced the efficacy of local treatment by using IL-2, IFN-α, and GM-CSF and omitting gardiquimod. As shown in Fig. 4 , under these circumstances vaccination with peptide-pulsed female lymphoblasts appeared to boost the effect of local treament. In another similar experiment, the combined treatment resulted in 7/10 of the mice showing complete or partial rejection, whereas vaccination alone and local treatment alone produced, respectively, 3/10 and 1/5 complete or partial rejections. Vaccination with the two peptides alone was ineffective.
Systemic Effects in Mice and Humans. For the combination of therapeutic vaccination and local immunostimulation to be effective in the treatment of human metastatic cancer, it is not sufficient to obtain rejection of the metastases that are treated locally. The rejection must result in such an activation of the immune effectors that they acquire the ability to eliminate the other metastases that have not been treated. A majority of the mice that received a local treatment either with IL-12 and IFN-α or with IL-2, IFN-α, and gardiquimod rejected subsequent grafts in the absence of further local treatment, indicating a degree of systemic increase of anti-HY memory T cells in these mice (Table S3) . However, when female mice grafted with male skin on both flanks received treatment only on the right graft, only modest effects were observed on the left graft. Even in those mice where the right graft was completely rejected, most left grafts remained intact (Table S4) . Moreover, it is possible that rejection of some of the untreated left grafts was due to a systemic effect of the cytokines, rather than being due to the activation of anti-HY lymphocytes resulting from the rejection of the treated grafts.
Nevertheless, we felt that the situation encountered with cancer patients might differ in this respect from that encountered with male skin grafts on female mice because the immune system of cancer patients appears to mount a considerable T-cell response against a multiplicity of tumor-specific antigens before becoming anergic. We therefore initiated a small clinical trial involving patients with metastatic melanoma. Before initiating the trial, we performed an experiment on mice with the combination of TLR-7 ligand imiquimod (Aldara cream), which replaced gardiquimod, and IL-2, IFN-α, and GM-CSF injected at the same location, but in separate syringes, as requested for the patients. The results were identical to those obtained with the combination involving gardiquimod (Fig. S5) .
Three HLA-A2 patients expressing the NA17 tumor-specific antigen (21) were treated, receiving four rounds of vaccination with the NA17.A2 peptide at 2-wk intervals. After each of the third and fourth rounds, these patients received a local treatment on one or two superficial metastases, namely six peritumoral injections of a low dosage of IL-2, IFN-α, and GM-CSF and two topical applications of imiquimod (Aldara cream) (Fig. S6) . One patient showed no response to the treatment, but interesting observations were made of the two other patients.
The first of these patients had previously been treated with a tyrosinase-A2 vaccine without response. This patient had about 40 cutaneous leg metastases. He was vaccinated with the NA17. A2 peptide, and two cutaneous metastases received the local treatment. Two months after the end of the treatment, the majority of the cutaneous metastases had completely regressed and 2 mo later all metastases had completely or partially regressed.
The second patient had been treated in the preceding months with a MAGE-A3 protein vaccine without observable effects. He had eight cutaneous leg metastases. He was vaccinated with the NA17.A2 peptide, and the local treatment was applied to two metastases. No immediate effect was observed, and 1 mo later the patient received four courses of dacarbazine, again without clinical response. Four months later, i.e., 7 mo after the end of our treatment, a routine examination revealed that all of the cutaneous metastases had undergone very significant regression. A metastasis in a mediastinal node had also regressed. However, a few months later this patient relapsed in several locations, including one of the treated metastases.
These observations are only suggestive, but they do open the possibility that the rejection process occurring in locally treated metastases can spread to untreated ones.
Discussion
We show here that local immunostimulatory treatments involving certain combinations of cytokines and TLR ligands can reactivate stalled T-cell responses against male mouse skin grafts. As it is highly unlikely that skin grafts develop particular ways to counteract immune rejection responses, we expect that the local immunostimulatory approaches described here would contribute to the reactivation of all stalled T-cell rejection responses observed in tumors as well as in grafts.
We do not understand why the T-cell responses against male skin grafts become stalled in CBA female mice. However, relevant observations have been made in CBA females that were injected with male spleen cells (22) . Here, most mice did not reject the male spleen cells but some did. When tetramerselected anti-HY CD8 T cells were transferred into responder mice, they expanded, whereas they did not in nonresponder mice. In line with this, significantly higher numbers of CD4 Thirty female CBA mice received a male skin graft. Forty days after grafting, we initiated local treatment with gardiquimod, IL-2, IFN-α, and GM-CSF as described in Fig. 3 . The 18 mice showing onset of rejection after 2 wk were divided at random into two equal groups. For the first group the treatment was halted, and for the second group the treatment was pursued either until complete rejection or the end of the sixth week. The 12 mice showing onset of rejection after 3-5 wk were also divided into a treatment and a nontreatment group.
The type of tolerance encountered in our system has been named "in vivo anergy" or "adaptative tolerance" (23) . Recent work indicates that a multiplicity of factors may contribute to the complex process leading to the establishment of T-cell anergy. The inhibition of IL-2 production and signaling pathways and that of the PI3 kinase-AKT-mTOR pathways appears to be a particularly crucial element in this process (24) . IL-2 is a crucial factor for Treg activity. In this respect, it is interesting to note the essential role of IL-2 observed here in combination with gardiquimod but also the lack of efficacy of IL-2 alone.
Several reports have described the use of cytokines, TLR ligands, or activating antibodies, such as anti-CD40, for intralesional treament of mouse or human tumors (25, 26) . Impressive results have been obtained on cutaneous metastases of melanoma patients (27, 28) . Our approach focuses on the search for synergic combinations of various cytokines and TLR ligands with the aim of obtaining immune rejection with much lower dosages (50-500×) than those reported previously. This ought to minimize harmful side effects.
Local immunostimulation is presently difficult to apply to metastases other than those that are cutaneous or subcutaneous. Moreover, the treatment involves injections of inflammatory agents in a territory that is highly inflamed by the previous injections. This can be painful. However, we have little doubt that technical advances will overcome both difficulties. In particular, it should be possible to trap the agents into capsules that will ensure slow, long-term delivery (29, 30) . This could reduce the frequency of injections to once a week.
The purpose of this report is to stimulate clinical cancer immunotherapy research combining vaccination with local and systemic immunostimulatory agents. We are convinced that local immunostimulation should be supplemented with vaccination against specific tumor antigens. The influx into the tumor of antitumor T cells, which have been freshly produced by the vaccination and therefore have not yet been rendered anergic, may prove to be a key condition for success. Considering the absence of toxicity observed with antitumor vaccination and the extremely low dose of immunostimulatory agents applied locally, we expect this combination treatment to produce very little or no toxicity. The combinations of immunostimulatory agents described here could be used in a first step. Additional agents could be put into play later. Agents that counteract immunosuppressive factors produced or elicited by cancer cells may be particularly useful. A low systemic dosage of anti-PD1, anti-PDL1, or anti-CTLA-4 might provide added efficacy without provoking autoimmune side effects. Perhaps our cancer immunotherapy strategies should emulate the immune system by administering a multiplicity of agents that complement each other.
Materials and Methods
Mice. CBA/Ca (CBA) and C57BL/6 mice were purchased from Harlan or produced under specific pathogen-free (SPF) conditions in the animal facility of the Ludwig Institute, Brussels Branch. C6ab TCR transgenic mice expressing a TCR specific for the Y-chromosome-derived male antigen HY K k Smcy were bred in our facility (31, 32) . The strain is on a CBA/Ca background. Mice were used at the age of 6-10 wk. All animal procedures were approved by the Institutional Review Board of the Université Catholique de Louvain.
Skin Grafts. Skin grafts were performed essentially according to the method of Billingham and Medawar (33) using tail skin grafted onto the lateral thorax. Ten days later the plaster cast was removed. A minimum of 20 d elapsed before any local treatment was performed on the graft to ensure perfect healing of the graft with the surrounding skin and the onset of hair regrowth.
Skin Graft Rejection Monitoring. We designated grafts as completely rejected when at least 90% of the surface of the graft showed scabbing, crust formation, and hair loss. At that point, it was difficult to ascertain whether any part of the graft had remained intact. The designation "mice with graft survival" corresponds to those with grafts that were not completely rejected. In most instances, these grafts were intact by the end of the observation period. We designated grafts as partially rejected when 20-90% of the graft showed scabbing, crust formation, and hair loss.
Cytokines. IL-1α, GM-CSF, IL-2, IL-18, IFN-α, and gardiquimod were purchased (SI Materials and Methods). Recombinant murine IL-12 was produced as described (34) .
Local Treatment of the Grafts. The cytokines were diluted and mixed with PBS containing 1% of CBA mouse serum. A volume of 100 μL was injected s.c. under the graft using a 30-gauge needle. The point of penetration was located about 1 mm outside the boundary of the graft and varied between Female CBA mice received an i.p. injection of 15.10 5 spleen CD8 T cells transgenic for the T-cell receptor directed against the K k HY peptide. One day later, these mice received a male skin graft. Three weeks later, the graft was treated locally with the agents indicated for 2 consecutive weeks. Gardiquimod was injected once a week. The other reagents were injected on the first, second, and fourth day of each week. The graft tissue was collected 1 wk after the end of treatment. The DNA was extracted, and the number of specific T-cell-receptor-coding DNA sequences was evaluated by PCR. The results represent the average of four mice. The total number of transgenic T cells is presented based on estimates of a total number of nucleated cells of 2.10 6 in the graft, 2.10 7 in the blood, and 7.10 7 in the spleen. We observed large differences between individual mice. 
